เกี่ยวกับตอนนี้
Recce Pharmaceuticals Ltd chief executive James Graham talked with Proactive about the company’s Phase 3 trial of RECCE® 327 Gel, or R327G, for the treatment of diabetic foot infections in Indonesia and the upcoming review of trial data by an independent Data Monitoring Committee.
Graham said the study is targeting a significant unmet medical need, highlighting the prevalence of diabetes across Indonesia and the wider ASEAN region and the risk that diabetic ulcers can become infected. He said R327G is being positioned as a potential treatment specifically for diabetic foot ulcer infections.
Data from 75 patients has been submitted to the independent Data Monitoring Committee, which will assess the study’s efficacy and safety findings. Graham explained that the decision followed a review involving local and international infectious disease experts.
Graham also discussed the broader commercial opportunity in diabetic foot infections, the gel’s topical application directly to infected ulcers and Recce Pharmaceuticals’ wider anti-infective development pipeline.
That pipeline includes further work targeting the US market as well as US Department of Defense programs involving burn wound infections, surgical wound infections and chemical countermeasure threats.
Visit Proactive’s YouTube channel for more interviews and company updates. If you found this video useful, give it a like, subscribe to the channel and enable notifications for future content.
#ReccePharmaceuticals #RCE #R327G #RECCE327 #Phase3 #ClinicalTrial #DiabeticFootInfection #DiabeticFootUlcer #AntibioticResistance #AntiInfectives #Biotechnology #BiotechStocks #ASX #Healthcare #DrugDevelopment #Superbugs #JamesGraham #ProactiveInvestor
Graham said the study is targeting a significant unmet medical need, highlighting the prevalence of diabetes across Indonesia and the wider ASEAN region and the risk that diabetic ulcers can become infected. He said R327G is being positioned as a potential treatment specifically for diabetic foot ulcer infections.
Data from 75 patients has been submitted to the independent Data Monitoring Committee, which will assess the study’s efficacy and safety findings. Graham explained that the decision followed a review involving local and international infectious disease experts.
Graham also discussed the broader commercial opportunity in diabetic foot infections, the gel’s topical application directly to infected ulcers and Recce Pharmaceuticals’ wider anti-infective development pipeline.
That pipeline includes further work targeting the US market as well as US Department of Defense programs involving burn wound infections, surgical wound infections and chemical countermeasure threats.
Visit Proactive’s YouTube channel for more interviews and company updates. If you found this video useful, give it a like, subscribe to the channel and enable notifications for future content.
#ReccePharmaceuticals #RCE #R327G #RECCE327 #Phase3 #ClinicalTrial #DiabeticFootInfection #DiabeticFootUlcer #AntibioticResistance #AntiInfectives #Biotechnology #BiotechStocks #ASX #Healthcare #DrugDevelopment #Superbugs #JamesGraham #ProactiveInvestor
ภาษาอังกฤษ
สหรัฐอเมริกา
สำเนาบทสนทนา 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
ค้นหาตอนที่ผ่านมา
ค้นหาตอนที่ผ่านมาของ Proactive - Interviews for investors
ตอนอื่นๆ ใน PODCAST นี้
Cascade Copper CEO Jeff Ackert joined Steve Darling from Proactive to discuss recent drilling results at the company’s Centerfire project in Ontario, plans for a second phase of exploration and preparations for drilling at the Copper Plateau project in British Columbia.
Ackert explained that Casca…
OTC Markets Group Head of APAC, International Corporate Services Stephen Shipley talked with Proactive about the company’s strategy for expanding its presence across the Asia-Pacific region and helping international companies improve access to US investors.
Speaking from Sydney during IMARC, Shipl…
S&U PLC (LSE:SUS) chairman Anthony Coombs spoke with Proactive's Stephen Gunnion about the group’s new £600 million funding facilities, which replace £330 million of existing arrangements at improved rates and support its next phase of growth.
Coombs described the deal as transformational, giv…
Midnight Sun Mining Corp Vice President of Business Development Adrian O’Brien joined Steve Darling from Proactive to provide an update on ongoing drilling at the company’s Dumbwa copper deposit in Zambia, where recent results are pointing to a significant expansion of the mineralized system in the…
Hive Digital Technologies Executive Chairman Frank Holmes Steve Darling from Proactive to discuss a major financing agreement for the company’s subsidiary, BUZZ High Performance Computing (BUZZ HPC), which has secured an approximately $129 million credit facility to fund advanced AI computing infra…
ข้อสงวนสิทธิ์: พอดแคสต์และอาร์ตเวิร์คที่ฝังอยู่ในหน้านี้มาจาก Proactive ซึ่งเป็นทรัพย์สินของเจ้าของและไม่มีส่วนเกี่ยวข้องหรือรับรองโดย Listen Notes, Inc.
